KEY DETAILS
Eli Lilly's trademark infringement (Lanham Act) lawsuit against MedShape Weight Loss Clinic LLC is pending in D. Ariz., with its latest docket activity dated October 8, 2026.
A Phase 4 trial recruiting at KU Leuven aims to find which patients respond best to semaglutide for binge eating.
Amgen's Phase 3 trial on at-home autoinjector use of maridebart cafraglutide has not started recruiting, with 230 participants planned.
Sheba Medical Center's Phase 2 ELITE trial on healthy aging has finished running, but its results are pending.
A preprint dated October 13, 2026 reported that adding nutrition therapy to incretin-based obesity care was associated with greater 12-month weight loss than care without it.
Five developments are covered here: one trademark court case and four research items. The lawsuit is pending, two trials are listed as not yet or currently recruiting, one trial has finished with results pending, and one preprint has not been peer reviewed.
Eli Lilly's lawsuit against MedShape Weight Loss Clinic is pending in federal court. Eli Lilly and Company v. MedShape Weight Loss Clinic LLC is filed in the District Court, D. Arizona, under the nature of suit "890 Other Statutes: Other Statutory Actions," with Eli Lilly and Company as plaintiff and MedShape Weight Loss Clinic LLC as defendant. The cause of action is listed as trademark infringement under the Lanham Act, which is an allegation, not a finding. The docket status is Pending, and its latest docket activity is dated October 8, 2026.
A Phase 4 trial recruiting at Universitaire Ziekenhuizen KU Leuven is trying to answer a specific question about semaglutide and eating behavior. The trial, A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating Spectrum, is sponsored by Universitaire Ziekenhuizen KU Leuven and is listed under identifier NCT07870538. Its goal is to investigate how GLP-1 receptor analogs, such as semaglutide (Wegovy), influence processes that determine eating behavior, binge eating, and weight regulation via the gut-brain axis, with the aim of identifying for whom semaglutide works best. Participants will receive six months of semaglutide treatment, attend two to four clinic visits, and wear a smartwatch while completing smartphone questionnaires, across a planned enrollment of 96 people. The trial covers obesity and overweight conditions and is listed as recruiting as of October 13, 2026.
Amgen's Phase 3 trial on at-home use of maridebart cafraglutide has not yet opened for recruitment. The study, Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight, is sponsored by Amgen and registered as NCT07871409, with a status of Not yet recruiting as of October 13, 2026. Its main objective is to assess whether participants can self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device, with a planned enrollment of 230 people. The trial's start date is listed as October 28, 2026, and completion is listed as September 8, 2027.
Sheba Medical Center's Phase 2 ELITE trial on healthy aging has finished running, though its results are pending. ELITE, short for Evidence-Based Longevity Interventions and Targeted Engagement, was a randomized, open-label, two-active-arm pilot conducted at Sheba Medical Center in Ramat Gan, Israel, with a status of Completed (results pending) as of October 13, 2026. The study aimed to characterize individual response to multidomain healthy-aging interventions over about eight weeks, combining a clinical measure of muscular, immune, and cognitive function with frequent digital monitoring between visits. Its primary outcome was the change from baseline to Week 8 in the Muscular-Immune-Cognitive Composite, and its listed start date was November 17, 2025, with completion listed as February 25, 2026.
A preprint posted to medRxiv looked at what happens when nutrition therapy is added to incretin-based obesity care. The preprint, Real-World Twelve-Month Weight Loss Outcomes in a Comprehensive Obesity Care Program Utilizing Individualized Nutrition Therapy and Incretin-Based Obesity Medications, carries the identifier 10.64898/2026.10.09.26365158 and is dated October 13, 2026, with a status of preprint, not peer reviewed. It found that integrating individualized carbohydrate-reduced nutritional therapy with incretin-based obesity medication care was associated with greater 12-month weight loss than incretin-based care without structured nutritional therapy. The authors describe this as support for further evaluation of individualized nutritional approaches as an adjunct to incretin-based obesity pharmacotherapy. Keep in mind that this has not yet been peer reviewed.
That is five developments: a pending lawsuit, two trials that are recruiting or not yet recruiting, one completed trial with results pending, and one preprint that has not been peer reviewed. The court docket, the trial registrations on ClinicalTrials.gov and the medRxiv preprint are the places where updates would appear.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.